Table 1 Statistical analysis of S100A7 immunoreactivity and clinicopathological parameters
Pathological parameters | S100A7 immunoreactivity | P value | |
|---|---|---|---|
Negative (−) | Positive (+) | ||
n = 103 | n = 47 | ||
Age, years | 56.6 ± 1.3 | 53.4 ± 1.9 | 0.149 |
Menopausal status | |||
 Premenopausal | 37 (24.7%) | 22 (14.7%) | 0.213 |
 Postmenopausal | 66 (44.0%) | 25 (16.7%) |  |
Stage | |||
 I | 58 (39.2%) | 18 (12.2%) | 0.016 |
 II | 35 (23.6%) | 16 (10.8%) |  |
 III | 9 (6.1%) | 12 (8.1%) |  |
Estrogen receptor status | |||
 Positive | 90 (60.8%) | 31 (20.9%) | 0.0012 |
 Negative | 11 (7.4%) | 16 (10.8%) |  |
Progesterone receptor status | |||
 Positive | 64 (43.2%) | 16 (10.8%) | 0.0013 |
 Negative | 37 (25.0%) | 31 (20.9%) |  |
HER2/neu status | |||
 Positive | 9 (6.1%) | 7 (4.7%) | 0.272 |
 Negative | 92 (62.2%) | 40 (27.0%) |  |
Ki-67 LI | 12.1 ± 1.2 | 21.3 ± 1.7 | <0.0001 |
Histological grade | |||
 1, 2 (well, moderate) | 79 (54.1%) | 21 (14.4%) | 0.027 |
 3 (poor) | 28 (19.2%) | 18 (12.3%) |  |
Lymph node metastasis | |||
 Positive | 27 (18.2%) | 21 (14.2%) | 0.038 |
 Negative | 74 (50.0%) | 26 (17.6%) |  |